SEATTLE, June 13, 2012 /PRNewswire/ -- Novo Nordisk (NYSE: NVO) hosted a community event today to celebrate the official opening of Novo Nordisk's new type 1 Diabetes R&D Center in Seattle, which will explore innovative approaches to treat and prevent type 1 diabetes.
Novo Nordisk, a leader in diabetes care, is the largest global manufacturer of insulin. The new center will combine Novo Nordisk's longstanding history of innovation and diabetes treatment with the company's growing expertise in immunotherapy.The event featured a keynote address from Governor Chris Gregoire, as well as remarks from Congressman Jim McDermott (WA-7), Novo Nordisk's Senior Leadership, key community leaders, and local diabetes patients. "This new research facility represents hope for everyone affected by type 1 diabetes," said Gov. Gregoire. "Developing better treatments for this chronic and costly disease – and the possibility of even finding a cure – is a critically important mission as the number of people with type 1 diabetes continues to increase. The State of Washington looks forward to the innovation that will take place here in close collaboration with the local and national research communities in type 1 diabetes." The unique concept behind the new center is to pursue a translational research approach characterized by combining basic research and early proof-of-concept trials under one umbrella. This integrated research approach provides the necessary scientific foundation to move early-stage discovery projects rapidly from animal models into small clinical exploratory trials in type 1 diabetes. Novo Nordisk was drawn to Seattle because of its strong reputation for public-private scientific collaboration and the talented biotech researchers who work here. "The diabetes R&D center is a welcome addition to the City of Seattle. The opening of this facility will represent 20 new jobs for our scientific community and an opportunity to showcase Seattle's biotech hub," remarked Rep. McDermott. The opening of this center will re-focus efforts on type 1 diabetes, a condition that has lacked major scientific progress in recent years. In the past decade, type 2 diabetes has been the main focus among diabetes researchers and pharmaceutical companies because of the dramatic rise in the number of people living with the disease. Type 1 diabetes is a different disease that requires life-saving treatment with insulin.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV